CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 67 enrolled
Drug / intervention
carboplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01525966
NCT01525966Phase 2Active

Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer

City of Hope Medical Center·interventional·Posted Feb 3, 2012·Updated Mar 30, 2026

In Brief

A Phase 2 clinical trial evaluating carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, and 1 other intervention for Inflammatory Breast Cancer and 9 related conditions. Active but no longer recruiting, targeting 67 participants across 2 sites.

Detailed Summary

This phase II trial studies how well carboplatin and nab-paclitaxel before surgery work in treating patients with triple negative breast cancer that is inflammatory or has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Study Details

Timeline

Phase 2Active
2012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 3, 2012
Enrollment StartFeb 15, 2012
Primary CompletionJan 11, 2019
Study CompletionNov 11, 2026
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 14.4 years ago

Interventions

carboplatindrug

Given IV

paclitaxel albumin-stabilized nanoparticle formulationdrug

Given IV

laboratory biomarker analysisother

Correlative studies